Novoclem announces CEO Anne Whitaker to present at the Biotech Showcase™
Jan 4, 2018
DURHAM, NC ( Jan. 4, 2018) – Novoclem Therapeutics, a preclinical-stage pharmaceutical company focused on helping people who suffer from severe respiratory diseases to breathe better and live life more fully, today announced that it will present at Biotech Showcase™ 2018, to be held January 8th –10th at the Hilton San Francisco Union Square.
Novoclem announces issuance of patent covering a core technology
Jan 3, 2018
Newly issued patent covers water soluble polyglucosamine compositions which release Nitric Oxide in a controlled and targeted manner
DURHAM, NC ( Jan. 3, 2018) – Novoclem Therapeutics today announced that U.S. Patent No. 9,850,322, “Water Soluble Nitric Oxide-Releasing ….
Novoclem Therapeutics, Inc. Receives QIDP Status for Its Lead
November 7, 2017
DURHAM, NC ( November 7, 2017 ) – Novoclem Therapeutics, Inc., today announced that its lead inhaled antimicrobial drug candidate, BIOC51, has been designated as a “Qualified Infectious Disease Product” (QIDP) by the U.S. Food & Drug Administration. The QIDP designation, granted for treatment of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with ….
Sign up for Email Alerts
Please fill out the form below to receive company press releases via email when they occur.